SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48 | -23.8% | 13,756 | +1.9% | 0.00% | – |
| Q2 2023 | $63 | 0.0% | 13,499 | -0.5% | 0.00% | – |
| Q1 2023 | $63 | -75.2% | 13,568 | -56.8% | 0.00% | – |
| Q4 2022 | $254 | -99.8% | 31,393 | +64.2% | 0.00% | – |
| Q3 2022 | $106,000 | +7.1% | 19,122 | +0.6% | 0.00% | – |
| Q2 2022 | $99,000 | -61.5% | 19,015 | -39.2% | 0.00% | – |
| Q1 2022 | $257,000 | -44.7% | 31,278 | 0.0% | 0.00% | – |
| Q4 2021 | $465,000 | -21.5% | 31,278 | -0.2% | 0.00% | -100.0% |
| Q3 2021 | $592,000 | -15.1% | 31,353 | -16.3% | 0.00% | 0.0% |
| Q2 2021 | $697,000 | +30.3% | 37,467 | +59.4% | 0.00% | 0.0% |
| Q1 2021 | $535,000 | +4.9% | 23,500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $510,000 | +359.5% | 23,500 | +113.6% | 0.00% | – |
| Q3 2020 | $111,000 | +30.6% | 11,000 | 0.0% | 0.00% | – |
| Q2 2020 | $85,000 | -24.1% | 11,000 | 0.0% | 0.00% | – |
| Q1 2020 | $112,000 | -7.4% | 11,000 | 0.0% | 0.00% | – |
| Q4 2019 | $121,000 | +21.0% | 11,000 | 0.0% | 0.00% | – |
| Q3 2019 | $100,000 | -20.0% | 11,000 | 0.0% | 0.00% | – |
| Q2 2019 | $125,000 | +861.5% | 11,000 | +900.0% | 0.00% | – |
| Q1 2019 | $13,000 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |